Figure 3
Figure 3. IL-7 adjuvant treatment elicits up-regulation of Bcl-2 in Tet+ and Tet−CD8+ T cells. Histogram plots show ex vivo expression of Bcl-2 in Tet+ (top panels) and Tet− (bottom panels) CD8+ T cells upon recombinant lentivector/Melan-A26-35 immunizations without (black line) or with rIL-7 treatment (gray line; days 10-23), at the indicated time point after immunization. The shaded area represents isotype control staining. The percentage of CD8+ T cells (M1) that up-regulated Bcl-2 expression upon rIL-7 treatment, and Bcl-2 expression levels (MFI) in those cells, as well as in cells from untreated mice, are indicated for every time point. The gray bar at the bottom of the plots represents the duration of IL-7 treatment.

IL-7 adjuvant treatment elicits up-regulation of Bcl-2 in Tet+ and TetCD8+ T cells. Histogram plots show ex vivo expression of Bcl-2 in Tet+ (top panels) and Tet (bottom panels) CD8+ T cells upon recombinant lentivector/Melan-A26-35 immunizations without (black line) or with rIL-7 treatment (gray line; days 10-23), at the indicated time point after immunization. The shaded area represents isotype control staining. The percentage of CD8+ T cells (M1) that up-regulated Bcl-2 expression upon rIL-7 treatment, and Bcl-2 expression levels (MFI) in those cells, as well as in cells from untreated mice, are indicated for every time point. The gray bar at the bottom of the plots represents the duration of IL-7 treatment.

Close Modal

or Create an Account

Close Modal
Close Modal